Curated News
By: NewsRamp Editorial Staff
April 06, 2026
TechForce & Oncotelic Partner on AI Robotics for Pharma Manufacturing
TLDR
- Nightfood Holdings' TechForce Robotics gains an edge by partnering with Oncotelic to develop AI-enhanced robotic systems for pharmaceutical manufacturing, targeting improved efficiency and scalability.
- The collaboration combines TechForce's robotics engineering with Oncotelic's AI-driven pharmaceutical technologies to create GMP-compliant robotic systems for laboratory automation and biopharma production.
- This partnership aims to enhance pharmaceutical manufacturing efficiency and compliance, potentially accelerating drug development and improving healthcare outcomes through advanced automation.
- Nightfood Holdings expands from hospitality robotics into regulated healthcare markets through an AI-enhanced robotics partnership with Oncotelic Therapeutics for pharmaceutical manufacturing automation.
Impact - Why it Matters
This collaboration represents a significant advancement at the intersection of robotics, artificial intelligence, and pharmaceutical manufacturing. For the biopharma industry, it promises to address critical pain points like production efficiency, stringent regulatory compliance (GMP), and scalability—factors that directly influence drug development timelines, costs, and ultimately, patient access to new therapies. By automating complex laboratory and manufacturing processes with AI-enhanced systems, this partnership could reduce human error, increase throughput, and lower operational expenses. For investors and industry observers, it signals TechForce Robotics' successful pivot from commercial applications into the high-value, regulated healthcare sector, potentially opening new revenue streams and validating the broader applicability of its automation platform. In an era where precision and speed in drug production are paramount, especially for oncology and other critical treatments, such innovations could accelerate the delivery of life-saving medications to market.
Summary
Nightfood Holdings (OTCQB: NGTF), operating as TechForce Robotics, has announced a strategic joint development, manufacturing, and licensing agreement with Oncotelic Therapeutics (OTCQB: OTLC). This partnership aims to co-develop AI-enhanced, GMP-compliant robotic systems specifically for pharmaceutical manufacturing and laboratory automation. The collaboration merges TechForce's expertise in robotics engineering with Oncotelic's AI-driven pharmaceutical technologies, targeting significant improvements in efficiency, compliance, and scalability within biopharma production. This move marks a pivotal expansion for TechForce Robotics into highly regulated healthcare markets, leveraging the extensive experience of Oncotelic CEO Dr. Vuong Trieu in oncology, drug development, and AI-enabled innovation.
TechForce Robotics, a wholly-owned subsidiary of Nightfood Holdings, is an AI-enhanced service-robotics and automation company focused on developing, deploying, and scaling autonomous robotic solutions. Initially targeting hospitality, foodservice, and commercial applications through its Robotics-as-a-Service (RaaS) platform, the company is now strategically diversifying into the pharmaceutical sector. Nightfood Holdings' long-term vision involves expanding into additional verticals that require similar automation solutions, delivering scalable robotics to enhance efficiency, reliability, and revenue generation across industries.
The announcement was disseminated through TechMediaWire (TMW), a specialized communications platform within the Dynamic Brand Portfolio of IBN (InvestorBrandNetwork). TMW provides comprehensive distribution services, including access to wire solutions via InvestorWire, article syndication to over 5,000 outlets, enhanced press release features, and extensive social media distribution through IBN's network. For further details, readers can view the full press release, and for ongoing updates, the latest news relating to NGTF is available in the company's newsroom. This partnership underscores a growing trend where robotics and AI converge to address complex challenges in regulated industries like pharmaceuticals.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, TechForce & Oncotelic Partner on AI Robotics for Pharma Manufacturing
